Merith Basey’s Post

More serious concerns, if not outright opposition, to Bill C-64, the ill-considered and poorly constructed #pharmacare legislation, from another reputable organization ... add the CARP (Canadian Association of Retired Persons) to a roster of groups that includes: ✴ Canadian Chamber of Commerce ✴ Canadian Organization for Rare Disorders ✴ Best Medicines Coalition ✴ Diabetes Canada ✴ Neighbourhood Pharmacy Association of Canada ✴ CLHIA ✴ Innovative Medicines Canada - Médicaments novateurs Canada This list is getting longer -- #patient groups, health charities, employers, insurers, and vast swaths of the #lifesciences ecosystem -- with each submission to, and testimony before, #hesa. These groups (and others) have provided thoughtful, detailed, and informed direction of what should be done, in what order, and by whom (feds - provinces - regulators - industry) to truly enhance access to medications across Canada and not compromise the life-extending and life-saving access that exists now, according to the The Conference Board of Canada, for the massive majority of Canadians. The ideology masquerading as intent that underpins Bill C-64 will ultimately hurt Canadians and irreparably damage #healthoutcomes and as an unintended consequence, further restrict access to innovative medications. Instead of supporting #healthequity, as presently written and "tabled", it will exacerbate our current postal-code/patchwork reality. Public and private #leadership, not legislation, is required to fill-the-gaps for the un-insured and under-insured ... ASAP, if not, like, yesterday! #cdnpoli #cdnhealth

Initiate is attending the World Orphan Drug Congress 2024 in Boston, USA, 23-25 May 2024. Are you attending? If you are do get in touch to set up a meeting with Andrew Mumford, CEO at Initiate, to discuss ways in which our team can support you with your reimbursement, market access and health economic challenges. #WODC24 #raredisease #marketaccess #reimbursement #healtheconomics

📢 Connecticut House Bill 5249 has been introduced. 🔍 Summary: Personal Opioid Drug Deactivation and Disposal Systems Connecticut House Bill 5249, introduced during the 2024 legislative session, focuses on enhancing opioid safety. Here are the key points: 1. Objective: To require pharmacies and pharmacists to provide personal opioid drug deactivation and disposal systems to patients. To dedicate funds from the Opioid Settlement Fund for reimbursing pharmacies and pharmacists for these systems. 2. Details: Pharmacies and pharmacists must offer safe disposal options for unused opioids. The goal is to prevent misuse and accidental exposure. The bill emphasizes community health and safety. 3. Impact: Positive: Empowers patients to safely dispose of opioids. Cost Coverage: Ensures reimbursement for pharmacies and pharmacists. Public Health: Addresses the opioid crisis. Stay ahead of regulatory changes with RegComply™! Whether you’re a healthcare organization, manufacturer, or pharmacy, our cutting-edge alert management platform ensures that the right alerts reach the right people, every time. Boost compliance, streamline regulatory processes, and enhance patient care. Schedule your demo today and experience the power of RegComply! https://d2rx.com/ #Connecticut #Healthcare #OpioidSafety #Legislation

As science unlocks new approaches to treating disease, many new medicines offer the potential to treat multiple conditions and transform patients’ lives. Our recent review of access to medicines with multiple indications show that they have a disproportionate rate of termination during NICE appraisal. Such medicines accounted for 65.1% (n=41) of total terminations in NICE since 2016, despite representing only 57.1% (n=226) of total submissions. Across submissions for all medicines, terminations at NICE have increased threefold in the past three years from 7-21. These trends raise serious questions regarding systemic barriers that could impact on patient access to medicines. They reflect a life sciences environment in the UK that is increasingly challenging and has become a disincentive to innovation. It is vital that the UK health system evolves, to ensure that innovative and cost-effective treatments continue to reach patients. #SanofiUK

In this update, #SyenzaTeam covers how to pay for universal access to rare disease medicines. 1️⃣ The UK's innovative pricing strategies and managed access agreements aim to balance cost and care effectiveness. 2️⃣ The UK has shifted its pricing strategy to include severity modifiers, allowing for higher payment thresholds for severe conditions. 3️⃣ Managed access agreements facilitate real-world evidence collection, yet burden healthcare professionals with data management tasks. 📊 Are we truly making strides towards fair drug pricing, or merely patching a widening gap? #pharmaceuticalindustry #marketaccess #heor #medicaldevices #healtheconomics #outcomesresearch #hta

On Friday, February 2nd 2024, our Executive Director Melissa Gong Mitchell participated in a panel discussion hosted by National Minority Quality Forum (NMQF).   Melissa joined experts from the Community Access National Network (CANN) and NATIONAL BLACK CAUCUS OF STATE LEGISLATORS (NBCSL) to discuss the current landscape on state prescription drug affordability boards (PDABs) as more states consider the implementation of these boards to address drug costs, and the impact PDABs can have on patient access, care delivery, innovation, and health equity.   💡KEY TAKEAWAY: The implementation of PDABs must prioritize and address concerns related to restricting access to therapies, particularly for marginalized communities, rather than constraining access harm due to financial risk mitigation, creating undue patient harm. Collaborative efforts among diverse communities to increase awareness and education of the unintended consequences are essential to prevent PDABs from impeding access to breakthrough treatments and worsening health disparities.   Watch the webinar recording at NMQF’s YouTube channel here: https://lnkd.in/g7_4i3nT

📋 As elderly patients age, they often find themselves managing multiple medications, a phenomenon known as polypharmacy. However, this practice increases the risk of adverse drug reactions and interactions, posing significant challenges to healthcare professionals. To address this issue, it is essential for healthcare providers to regularly review the patient’s medication list and simplify the regimen whenever possible. 💊 #SeniorHealth #Polypharmacy #MedicationManagement 🌿 https://lnkd.in/dNWkci94

We welcome the news that Boehringer Ingelheim is capping the price of asthma inhalers at $35 a month. https://lnkd.in/gDf97tyh   AAFA continues to work with all stakeholders across the complex U.S. drug pricing ecosystem to ensure that essential medicines are available at an affordable price for those who need them most.   Access to asthma medications can save lives, reduce hospitalizations, and lower the more than $82 billion in annual costs to the U.S. economy from this chronic disease. But the U.S. health care system is complex, and often leaves patients with few affordable options.   We will continue to raise awareness of the importance of improving access to treatment by lowering drug costs.   #Asthma #RespiratoryHealth #CommunityHealth #DrugPricing

Economics plays a central role in Hatch-Waxman, BPCIA and additional pharma regulations that try to balance incentives for innovation with accessibility. Yet, other pharma regulations seemingly fall short of making full use of economics. One example: The concern that the FDA's Accelerated Approval program, which accelerates the approval of drugs that fill an unmet medical need, may sometimes result in unnecessary delays of confirmatory trials. Why is this a concern? Unnecessary delays may result in prolonged use of drugs that do not demonstrate any clinical benefit or sufficient clinical benefit to justify the risks associated with the drug. In this article, I discuss how we can reduce these risks with policy changes based on economic fundamentals at the heart of H-W and BPCIA. #healthpolicy #pharmaceuticals

Pharmacy 777 supports Penington Institute's International Overdose Awareness Day. IOAD aims to spread the important message that the tragedy of drug overdose death and drug overdoses is preventable.  This year’s theme is “Recognising those people who go unseen,” and we honour the people whose lives have been altered by overdose. Tragically, thousands of Australians lose their lives every year due to unintentional drug overdose. The Penington Institute’s Annual Overdose Report 2023 shows that since 2001 there have been 37,000 drug-induced deaths in Australia. Pharmacy 777 Managing Director Kim Brotherson shares his perspective on the rising concern of medication overdose “To save lives and reduce the high number of patients hospitalised due to medication-related overdose, healthcare professionals, including pharmacists are committed to harm minimisation measures.” Read more: https://lnkd.in/gkHyzU24 #IOAD2023 #weseeyou #EndOverdose